Perception and predictability of travel fatigue after long-haul flights: a retrospective study.

Aviat Space Environ Med

Centrica plc, Windsor, Berkshire, England, UK.

Published: February 2003

Background: The impact of travel fatigue and jet lag varies between individuals and may significantly affect the ability of some to perform their occupational role following a transmeridian flight. It would be advantageous in an occupational setting to be able to predict prior to travel those who may suffer most.

Methods: A Traveler Profile Questionnaire was developed to assess the perceived severity of travel fatigue in 100 subjects making transmeridian flights.

Results: The questionnaire provided an internally consistent measure of fatigue and confirmed that subjects experienced greater symptoms of travel fatigue following east/west flights when compared with north/south. Easterly travel was rated marginally worse than travel in a westerly direction. The respondents scores as measured by the Circadian Type Inventory (Folkard 1987) and Composite Morningness Questionnaire (Smith 1989) were used to identify whether such tools could be used as indicators of susceptibility to the effects of travel fatigue. After allowing for a gender difference, increased rigidity in sleeping habits as shown by a decrease in the Flexibility/Rigidity score on the Circadian Type Inventory was associated with an increase in the composite 'severity' score for travel fatigue derived from ratings of specific physiological symptoms.

Conclusions: The Traveler Profile Questionnaire, while internally consistent was nonetheless insufficient to be used in a predictive capacity to identify those individuals who would suffer most from the effects of travel fatigue.

Download full-text PDF

Source

Publication Analysis

Top Keywords

travel fatigue
28
travel
10
fatigue
8
traveler profile
8
profile questionnaire
8
internally consistent
8
circadian type
8
type inventory
8
effects travel
8
perception predictability
4

Similar Publications

Evidence of antihypertensive drug-related problems (aDRP) is limited in Asian ambulatory care. To better detect aDRP without causing alert fatigue, we investigated whether adding more antihypertensive agents was associated with increasing aDRP risk and factors associated with physician acceptance of aDRP correction. We conducted a cross-sectional study targeting ambulatory prescriptions of Vietnamese patients with hypertension who either received standard therapy (using two or fewer medications, SdT) or standard plus add-on therapy (using more than two medications, SdT + add-on).

View Article and Find Full Text PDF

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.

Lancet Respir Med

January 2025

Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Background: Recurrent respiratory papillomatosis (RRP) is a rare debilitating condition caused by chronic infection with human papillomavirus (HPV) type 6 or 11. Papillomas develop in the aerodigestive tract, leading to significant voice disturbance and airway obstruction. No systemic treatment currently exists.

View Article and Find Full Text PDF

Background: Francisella tularensis is an aerobic, gram negative coccobacillus bacterium that causes tularemia. F. tularensis spreads primarily through ticks, biting flies, droplet inhalation, contaminated mud or water, or infected animal bites, and it can survive in animal carcasses with the most common mode of transmission occurring via inoculation into the skin and inhalation/ingestion.

View Article and Find Full Text PDF

Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.

View Article and Find Full Text PDF

Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.

Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!